NEXT Oncology, an Avacare business

05/07/2026

Here’s to all the Oncology Nurses who are vital to the continuity of care for patients. We honor your care, advocacy and patient support.

Growing Hope and Inspiring Strength.

04/23/2026

We are happy to be a part of this Phase I trial with Pilatus Biosciences and to have dosed the first patient in our NEXT – Houston office!

https://www.pilatusbio.com/latest-news/pilatus-biosciences-announces-first-patientdosed-in-phase-1-trial-of-first-in-class-metaboliccheckpoint-antibody-plt012-in-solid-tumors

04/16/2026

April is Testicular Cancer Awareness Month. Testicular cancer is the most common form of cancer in 20- to 35-year-old men. Fortunately, caught early, it is highly treatable and can often be cured, according to the National Cancer Institute (NCI). Know the facts. Learn more here.

https://www.testicularcancerawarenessfoundation.org/statistics-risk-factors

04/09/2026

April is Esophageal Cancer Awareness Month. The statistics surrounding esophageal cancer are truly alarming, which makes awareness and education so important. This April, take a few minutes to learn the facts about esophageal cancer and become familiar with the symptoms and risk factors. It could be life-saving information for you or someone you love.

04/06/2026

Congratulations to our colleagues at Avacta Therapeutics for dosing the first patient in this important Phase I trial.

back to news 31 Mar 2026 Avacta announces first patient treated in Phase 1 FOCUS-01 trial of FAP-Exd (AVA6103) – a sustained-release pre|CISION® exatecan peptide drug conjugate Enrollment underway in second Avacta clinical program at first three specialist U.S. oncology centers Initial data from ...

03/18/2026

Congratulations to our colleagues at Cartography Biosciences for dosing the first patient in its Phase I trial.

Learn more here:

Cartography Biosciences, Inc., a clinical-stage biotechnology company advancing a differentiated pipeline of antibody-based cancer therapies, today announced...

03/12/2026

03/02/2026

March is Month - and early detection matters. Know the facts and talk to your physician about screening.

02/04/2026

This World Cancer Day, we honor the patients and researchers driving progress in cancer care. Phase 1 clinical trials are a vital first step in translating promising science into hope.

02/03/2026

These preliminary results from Aprea Therapeutics are encouraging - congratulations! We are proud to be part of this trial.

“These early single-agent data demonstrate that APR-1051 has clinical activity as a single agent. The observation of a partial response on the first scan, together with a decrease in tumor marker at this dose level, supports continued clinical evaluation of APR-1051," commented NEXT Oncology's founder Anthony Tolcher.

Approximately 50% reduction in target lesion and greater than 90% decrease in CA-125 observed in endometrial cancer patientThe unconfirmed partial response...